In the latest trading session, United Therapeutics (UTHR) closed at $93.90, marking a -0.98% move from the previous day.
The biotechnology industry is comprised of hundreds of companies that fuse biology and technology to develop drugs and related products for the treatment of diseases and medical conditions. Today's biotechnology industry includes companies that make medical devices and diagnostics, as well as biofuels, biomaterials, pollution controls, and more.
United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2020. First quarter net revenue decreased 2% to $356.3 million year-over-year while first quarter net revenue excluding Adcirca increased 0.4%…
Most readers would already be aware that United Therapeutics' (NASDAQ:UTHR) stock increased significantly by 18% over...
United Therapeutics Corporation (Nasdaq: UTHR) today detailed recent publications on Orenitram® (treprostinil) Extended-Release Tablets, which provide additional evidence of the beneficial treatment effect in patients with pulmonary arterial hypertension (PAH).
Zacks.com featured highlights include: SpartanNash Company, BG Foods, QIAGEN, Regeneron Pharmaceuticals and United Therapeutics
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and…
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 26, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview an…
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Bio-Rad Laboratories, Inc. Class A …
United Therapeutics (UTHR) beats estimates for both earnings and sales in first quarter. It expects a reduction in new patient starts in the future quarters. Stock down.
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * Arcturus Therapeuti…
Celularity Inc. ("Celularity" or the "Company"), a clinical-stage company developing allogeneic cellular therapies from human placentas, today announced the expansion of its existing collaborative license agreement with United Therapeutics Corporation's (Nasdaq: UTHR) wholly-owned subsidiary, Lung Biotechnology PBC, to include the treatment of COVID-19 and Acute Respiratory Distress Syndrome (ARDS).
As the month of May kicked off, stocks got off to a rocky start. The market slumped in response to a first quarter profit miss from eCommerce giant Amazon (NASDAQ:AMZN) and its plan to put all second-quarter earnings towards its COVID-19 response, with all th…
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 6, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and…
United Therapeutics (UTHR) delivered earnings and revenue surprises of 28.40% and 2.50%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 29, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2020. First quarter net revenue decreased 2% to $356.3 mil…
Does United Therapeutics (UTHR) have what it takes to be a top stock pick for momentum investors? Let's find out.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., April 29, 2020 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2020. First quarter net revenue decreased 2% to $356.3 mil…
UTHR earnings call for the period ending March 31, 2020.
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the BofA Securities Virtual Health Care Conference 2020.
Is (UTHR) Outperforming Other Medical Stocks This Year?
Is (UTHR) Outperforming Other Medical Stocks This Year?
Q1 2020 United Therapeutics Corp Earnings Call
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the BofA Securities Virtual Health Care Conf…
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Jefferies Virtual Health Care Conference.
It's my pleasure to welcome you to the United Therapeutics Corporation First Quarter 2020 Earnings Call. Accompanying me on today's call are Dr. Martine Rothblatt, our Chairman and Chief Executive Officer; Mr. Michael Benkowitz, our Present and Chief Operating Officer; Mr. James Edgemond, our Chief Financial Officer; and Dr. Leigh Peterson, our Vice President of Product Development.
United Therapeutics Corporation (Nasdaq: UTHR) announced today that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business during a fireside chat session at the Jefferies…
Q4 2019 United Therapeutics Corp Earnings Call
United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended March 31, 2020. First quarter net revenue decreased 2% to $356.3 million year-over-year while first quarter net revenue excluding Adcirca increased 0.4%, compared to the first quarter of 2019. First quarter diluted earnings per share (EPS) was $3.12 compared to an $11.32 per share loss in the first quarter of 2019. Non-GAAP diluted EPS of $3.61 was up 1% from the first quarter of 2019.
Zacks.com featured highlights include: SpartanNash, BG Foods, Regeneron, Vipshop and United Therapeutics